Cytek Biosciences Stock Market Outlook
| CTKB Stock | USD 4.24 0.07 1.68% |
About 77 percent of all Cytek Biosciences' investors are aggressively thinking of buying. The analysis of overall sentiment of trading Cytek Biosciences stock suggests that quite a large number of investors are excited at this time. The current market sentiment, together with Cytek Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Cytek Biosciences stock news signals to limit their universe of possible portfolio assets.
Comfort Level 77
Excited
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Cytek Biosciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Cytek Biosciences.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cytek Biosciences is 'Cautious Hold'. Macroaxis provides Cytek Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CTKB positions.
Execute Cytek Biosciences Advice
The Cytek recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Cytek Biosciences. Macroaxis does not own or have any residual interests in Cytek Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cytek Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weakest | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
For the selected time horizon Cytek Biosciences has a Mean Deviation of 2.66, Standard Deviation of 4.18 and Variance of 17.5We provide trade advice to complement the prevailing expert consensus on Cytek Biosciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Cytek Biosciences is not overpriced, please confirm all Cytek Biosciences fundamentals, including its cash per share, short ratio, and the relationship between the ebitda and current ratio . Given that Cytek Biosciences has a number of shares shorted of 6.54 M, we suggest you to validate Cytek Biosciences market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Cytek Biosciences Trading Alerts and Improvement Suggestions
| Cytek Biosciences generated a negative expected return over the last 90 days | |
| Cytek Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 105.23 M. | |
| About 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 |
Cytek Biosciences Returns Distribution Density
The distribution of Cytek Biosciences' historical returns is an attempt to chart the uncertainty of Cytek Biosciences' future price movements. The chart of the probability distribution of Cytek Biosciences daily returns describes the distribution of returns around its average expected value. We use Cytek Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cytek Biosciences returns is essential to provide solid investment analysis for Cytek Biosciences.
| Mean Return | -0.09 | Value At Risk | -4.99 | Potential Upside | 5.95 | Standard Deviation | 4.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cytek Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cytek Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.2 M | Northern Trust Corp | 2025-06-30 | 1.1 M | Renaissance Technologies Corp | 2025-06-30 | 1.1 M | Goldman Sachs Group Inc | 2025-06-30 | 1 M | Millennium Management Llc | 2025-06-30 | 924.8 K | Charles Schwab Investment Management Inc | 2025-06-30 | 909.6 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 888.3 K | Bank Of New York Mellon Corp | 2025-06-30 | 699.9 K | Ubs Group Ag | 2025-06-30 | 632.1 K | Blackrock Inc | 2025-06-30 | 17 M | Vanguard Group Inc | 2025-06-30 | 7.8 M |
Cytek Biosciences Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change To Inventory | (7.1M) | (17.7M) | 4.3M | 14.8M | 17.0M | 17.8M | |
| Investments | (21.0M) | (1.6M) | (174.0M) | (83.0M) | (74.7M) | (78.4M) | |
| Change In Cash | 198.5M | (65.1M) | (131.9M) | (68.9M) | (62.0M) | (58.9M) | |
| Net Borrowings | (2.8M) | 2.9M | (565K) | 3.6M | 3.3M | 3.4M | |
| Free Cash Flow | 266K | (22.1M) | 454K | 21.9M | 25.1M | 26.4M | |
| Depreciation | 1.2M | 5.7M | 9.2M | 10.5M | 12.1M | 12.7M | |
| Other Non Cash Items | 2.4M | 3.0M | (3.3M) | (10.8M) | (9.7M) | (9.2M) | |
| Capital Expenditures | 4.4M | 9.9M | 4.8M | 3.5M | 4.1M | 4.6M | |
| Net Income | 3.0M | 2.5M | (12.1M) | (6.0M) | (5.4M) | (5.1M) | |
| End Period Cash Flow | 364.6M | 299.5M | 167.6M | 98.7M | 113.6M | 206.6M |
Cytek Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cytek Biosciences or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cytek Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cytek stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.19 | |
β | Beta against Dow Jones | 1.46 | |
σ | Overall volatility | 3.33 | |
Ir | Information ratio | -0.04 |
Cytek Biosciences Volatility Alert
Cytek Biosciences exhibits very low volatility with skewness of 2.16 and kurtosis of 8.9. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cytek Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cytek Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cytek Biosciences Fundamentals Vs Peers
Comparing Cytek Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cytek Biosciences' direct or indirect competition across all of the common fundamentals between Cytek Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cytek Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cytek Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cytek Biosciences to competition |
| Fundamentals | Cytek Biosciences | Peer Average |
| Return On Equity | -0.0336 | -0.31 |
| Return On Asset | -0.0436 | -0.14 |
| Profit Margin | (0.07) % | (1.27) % |
| Operating Margin | (0.18) % | (5.51) % |
| Current Valuation | 305.24 M | 16.62 B |
| Shares Outstanding | 127.86 M | 571.82 M |
| Shares Owned By Insiders | 9.27 % | 10.09 % |
| Shares Owned By Institutions | 67.10 % | 39.21 % |
| Number Of Shares Shorted | 6.54 M | 4.71 M |
| Price To Book | 1.43 X | 9.51 X |
| Price To Sales | 2.75 X | 11.42 X |
| Revenue | 200.45 M | 9.43 B |
| Gross Profit | 105.23 M | 27.38 B |
| EBITDA | (10.03 M) | 3.9 B |
| Net Income | (6.02 M) | 570.98 M |
| Cash And Equivalents | 349.89 M | 2.7 B |
| Cash Per Share | 2.60 X | 5.01 X |
| Total Debt | 17.02 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 10.47 X | 2.16 X |
| Book Value Per Share | 2.96 X | 1.93 K |
| Cash Flow From Operations | 25.38 M | 971.22 M |
| Short Ratio | 8.03 X | 4.00 X |
| Earnings Per Share | (0.11) X | 3.12 X |
| Target Price | 6.0 | |
| Number Of Employees | 692 | 18.84 K |
| Beta | 1.3 | -0.15 |
| Market Capitalization | 542.15 M | 19.03 B |
| Total Asset | 499.5 M | 29.47 B |
| Retained Earnings | (35.2 M) | 9.33 B |
| Working Capital | 328.78 M | 1.48 B |
| Net Asset | 499.5 M |
Note: Disposition of 29002 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3 [view details]
Cytek Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cytek . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cytek Biosciences Buy or Sell Advice
When is the right time to buy or sell Cytek Biosciences? Buying financial instruments such as Cytek Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cytek Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Government Funds Thematic Idea Now
Government Funds
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cytek Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.